Yesterday, the Medicare Evidence Development and Coverage Advisory Committee’s (MEDCAC) vote on a number of questions amounted to a recommendation to the Centers for Medicare and Medicaid Services (CMS) to cover Provenge, a therapeutic vaccine for men with advanced prostate cancer. While the recommendation was not overwhelmingly enthusiastic, Provenge clears one hurdle on its way...Continue reading